Tolerogenixx

Description

Tolerogenixx develops personalized therapies using proprietary modified immune cell technology to target immune modulation, including MIC-Lx, an intravenous donor-cell product given before transplantation to induce donor-specific tolerance while preserving protective immune responses.

Related

• Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
• CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
• AAsgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• ScientaLabScientaLab develops a foundation model that predicts human immune response in immunology and inflammation, using multi-disease,…
• CCeraVxCeraVx develops ceramic CeraMaps microneedle patches for intradermal delivery of vaccines and medicines, using biocompatible, inert…
• ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…
• BioatlantisBioatlantis supplies natural compounds from renewable marine and terrestrial resources, including seaweed extracts, that reduce stress by…
• SciRhomSciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF…
• CytuvaxCytuvax develops cancer immunotherapy and vaccines for viral and bacterial pathogens, using depot-attached cytokines as immune-stimulating…